ArticlePLoS pathogens2007
Interfering residues narrow the spectrum of MLV restriction by human TRIM5alpha.
Article in PLoS pathogens, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- HIV capsids: orchestrators of innate immune evasion, pathogenesis and pandemicity.The Journal of general virology · 2025Review
- Mutational resilience of antiviral restriction favors primate TRIM5α in host-virus evolutionary arms races.eLife · 2020Article
- Article
- Restriction of HIV-1 and other retroviruses by TRIM5.Nature reviews. Microbiology · 2019Review
- Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.Human gene therapy · 2015Article
- Apparent effect of rabbit endogenous lentivirus type K acquisition on retrovirus restriction by lagomorph Trim5αs.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013Article
- Virus-specific effects of TRIM5α(rh) RING domain functions on restriction of retroviruses.Journal of virology · 2013Article
- A comparison of murine leukemia viruses that escape from human and rhesus macaque TRIM5αs.Journal of virology · 2013Article
- Gain-of-sensitivity mutations in a Trim5-resistant primary isolate of pathogenic SIV identify two independent conserved determinants of Trim5α specificity.PLoS pathogens · 2013Article
- The V86M mutation in HIV-1 capsid confers resistance to TRIM5α by abrogation of cyclophilin A-dependent restriction and enhancement of viral nuclear import.Retrovirology · 2013Article
- Structural insight into HIV-1 capsid recognition by rhesus TRIM5α.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Structure of the rhesus monkey TRIM5α PRYSPRY domain, the HIV capsid recognition module.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif (TRIM) proteins.The Journal of biological chemistry · 2011Article
- Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses.Journal of virology · 2011Article
- Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.The Journal of biological chemistry · 2011Article
- Characterization of a core fragment of the rhesus monkey TRIM5α protein.BMC biochemistry · 2011Article
- A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent.Retrovirology · 2010Article
- Generation of human TRIM5alpha mutants with high HIV-1 restriction activity.Gene therapy · 2010Article
- The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain.Journal of virology · 2010Article
- Paleovirology--modern consequences of ancient viruses.PLoS biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TRIM5alpha is a restriction factor that limits infection of human cells by so-called N- but not B- or NB-tropic strains of murine leukemia virus (MLV). Here, we performed a mutation-based functional analysis of TRIM5alpha-mediated MLV restriction. Our results reveal that changes at tyrosine(336) of human TRIM5alpha, within the variable region 1 of its C-terminal PRYSPRY domain, can expand its activity to B-MLV and to the NB-tropic Moloney MLV. Conversely, we demonstrate that the escape of MLV from restriction by wild-type or mutant forms of huTRIM5alpha can be achieved through interdependent changes at positions 82, 109, 110, and 117 of the viral capsid. Together, our results support a model in which TRIM5alpha-mediated retroviral restriction results from the direct binding of the antiviral PRYSPRY domain to the viral capsid, and can be prevented by interferences exerted by critical residues on either one of these two partners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.